|Title:||Genomic intensive care: should we perform genome testing in critically ill newborns?|
|Publisher:||BMJ Publishing Group|
|Citation:||Wilkinson DJC, Barnett C, Savulescu J, Newson A J, Genomic intensive care: should we perform genome testing in critically ill newborns? Archives of Disease in Childhood / ADC Fetal & Neonatal Edition (2015). 1–7. http://doi.org/10.1136/archdischild-2015-308568, published online 14 Sept 2015|
|Abstract:||In newborn intensive care units (NICUs), the science and art of prognostication often have life and death implications. Approximately 5% of infants admitted to NICU die.1 The majority of deaths are preceded by decisions to withdraw or withhold life-sustaining treatment,1 following discussions between the family and clinical team. These decisions are based on an assessment of an infant's chance of survival and on the predicted duration and nature of the infant's survival if treatment is provided.2 A variety of clinical, biochemical, genetic and radiological tests have traditionally been employed to estimate prognosis in the NICU. While chromosomal microarray is now commonly used for critically ill neonates with congenital malformations, new forms of genetic and genomic testing3 have started to become available in intensive care.4 They could aid critical care decision-making by predicting functional outcome, important comorbidities5 or poor prognosis despite treatment.|
|Type of Work:||Article|
|Appears in Collections:||Research Papers and Publications. Sydney Health Ethics|
|genomic-intensive-care-2015.pdf||256.12 kB||Adobe PDF|
Items in Sydney eScholarship Repository are protected by copyright, with all rights reserved, unless otherwise indicated.